Physician profile
Mark Rybakov
NPI 1295037620
$3,159.56
in general payments reported to CMS, 2019-2025
22 companies · $638 in 2025
The $638 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,269 · 2020: $124 · 2022: $153 · 2023: $298 · 2024: $677 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,612.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $1,040.84 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $543.25 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $188.96 | 2024-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $179.83 | 2019-2023 | Trintellix |
| Celgene Corporation | $150.73 | 2019 | |
| Alkermes, INC. | $138.66 | 2019-2024 | Aristada, Lybalvi, Aristada Initio |
| Viiv Healthcare Company | $122.15 | 2023-2025 | Apretude |
| Bausch Health US, LLC | $94.08 | 2024-2025 | Wellbutrin, Aplenzin |
| Teva Pharmaceuticals USA, INC. | $93.21 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $85.06 | 2024-2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $82.31 | 2019-2023 | Spravato |
| Sunovion Pharmaceuticals INC. | $66.45 | 2019 | |
| Abbvie INC. | $61.88 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.33 | 2023-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $57.65 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $52.40 | 2022-2024 | Qelbree |
| Almatica Pharma LLC | $31.21 | 2025 | Loreev Xr |
| Corium, LLC | $29.03 | 2023 | Azstarys |
| Neuronetics, INC. | $24.92 | 2024 | Neurostar Tms Therapy System |
| Collegium Pharmaceutical, INC. | $21.33 | 2025 | Xtampza |
| Glaxosmithkline, LLC. | $18.32 | 2024 | Trelegy Ellipta |
| Orexo US, INC. | $17.96 | 2023 | Zubsolv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rybakov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.